Sanjivani Paranteral
180.00
-0.20(-0.11%)
Market Cap₹221.15 Cr
PE Ratio26.58
IndustryHealthcare
Company Performance:
1D-0.11%
1M+12.99%
6M-14.37%
1Y-28.09%
5Y+1,478.95%
View Company Insightsright
More news about Sanjivani Paranteral
15Nov 25
Sanjivani Parenteral Reports Mixed Q2 Results with Revenue Decline and Stable EBITDA Margin
Sanjivani Parenteral Limited announced Q2 financial results with revenue declining 14.5% YoY to Rs. 155.00 crore and PAT decreasing 28.6% YoY to Rs. 16.40 crore. EBITDA margin remained stable at 15.5%. Injectables segment grew 2.4% YoY, while oral segment declined 35.4% due to shipment challenges. Exports contributed 81.6% of total revenue. Half-yearly total income decreased 4.1% to Rs. 335.90 crore, with PAT down 16% to Rs. 33.70 crore.
 no imag found
04Nov 25
Sanjivani Parenteral Limited Initiates Postal Ballot for Director Appointment
Sanjivani Parenteral Limited has initiated a postal ballot to appoint Mr. Basant Shrivastava as a Non-Executive Independent Director for a 5-year term starting September 11, 2025. Mr. Shrivastava, 69, brings over 40 years of pharmaceutical industry experience. E-voting will run from November 5 to December 4, 2025, with results expected by December 6. The Board of Directors recommends shareholders approve this appointment as an Ordinary Resolution.
 no imag found
11Sept 25
Sanjivani Paranteral Appoints Pharma Veteran Basant Shrivastava as Independent Director
Sanjivani Paranteral Limited has appointed Mr. Basant Shrivastava as an Additional Director in the Independent Category, effective September 11, 2025. Shrivastava, with 40 years of pharmaceutical industry experience, joins for a five-year term as a Non-Executive Independent Director. His appointment, subject to shareholder approval, was recommended by the Nomination and Remuneration Committee. Shrivastava's background includes leadership roles at Johnson & Johnson, Nelson Chemical, and current positions at Vita Pharma Agencies and Joint Force Pharma Ltd. He is known for his sales and marketing expertise in the pharmaceutical sector.
 no imag found
08Sept 25
Sanjivani Parenteral Launches Commercial Production at New IV Fluid Plant in Pune
Sanjivani Parenteral Limited has started commercial production at its new intravenous fluid infusion plant in Pune, Maharashtra. The facility, operated by subsidiary SPL Infusion Pvt. Ltd., began operations on September 6, 2025. The plant features advanced technology, sustainability initiatives including solar panels, and has obtained necessary manufacturing licenses. Located strategically in Pune, it aims to serve both domestic and export markets efficiently.
 no imag found
18Aug 25
Sanjivani Parenteral Reports 8.9% Revenue Growth in Q1, Pune Facility Set for Commercial Production
Sanjivani Parenteral Limited, a WHO-GMP certified pharmaceutical company, reported Q1 revenue growth of 8.9% YoY to INR 17.90 crores. EBITDA increased by 10.8% to INR 2.70 crores, with margins improving to 15.00%. The company maintains a 73.70%-26.30% export-domestic revenue mix, exporting to over 25 countries. Their new Pune facility is expected to begin commercial production by early September. The company added 8 new products in Q1 and Q2 combined and is focusing on expanding in LATAM and French-speaking African markets. Despite logistical challenges, management remains optimistic, providing a full-year revenue guidance of INR 75-80 crores.
 no imag found
12Aug 25
Sanjivani Paranteral Reports 8.9% Revenue Growth in Q1 FY26, Driven by Strong Injectables Performance
Sanjivani Paranteral Limited reported an 8.9% year-over-year revenue growth to ₹178.90 crore for Q1 FY26. EBITDA increased by 10.8% to ₹26.80 crore, while PAT grew marginally by 1.0% to ₹17.30 crore. The injectables segment showed robust growth of 47.1%, but the oral segment declined by 11.1% due to shipment challenges. Exports constituted 73.7% of total revenue, with core markets in CIS, Middle East & Africa, and Latin America contributing significantly. The company remains focused on R&D and expanding its product portfolio to drive future growth.
 no imag found
Sanjivani Paranteral
180.00
-0.20
(-0.11%)
1 Year Returns:-28.09%
Industry Peers
Sun Pharmaceutical
1,675.50
(-1.04%)
Divis Laboratories
6,229.00
(-1.02%)
Torrent Pharmaceuticals
4,179.50
(+0.57%)
Lupin
2,326.10
(-0.04%)
Dr Reddys Laboratories
1,235.70
(+1.17%)
Cipla
1,240.80
(+0.84%)
Zydus Life Science
943.95
(+0.52%)
Mankind Pharma
2,125.00
(+0.98%)
Aurobindo Pharma
1,386.00
(-0.04%)
Alkem Laboratories
5,582.00
(+0.22%)